| Hypersensitivity reactions to TNF-α inhibitors | Sevim BAVBEK | 1–5 |
| Epidemiological and overall survival characteristics of cancer patients in Ege University Hospital database | Ayfer HAYDAROĞLU,Fatma SERT,AYŞE CANER | 1–9 |
| Uveitis under anti-TNF therapy: Adverse effect or disease course? | Didem ARSLAN | 6–7 |
| Autoimmune diseases during anti-TNF therapy: Coexisting disease? Drug-induced? | Selda ÇELİK | 8–10 |
| Epidemiological and overall survival characteristics of central nervous system tumors in Ege University Hospital | Erkin ÖZGİRAY,K. Emre ÇALIŞKAN,M. Sedat ÇAĞLI,Taşkın YURTSEVEN,YEŞİM ERTAN,Taner AKALIN,Ulus ŞANLI,Serra KAMER,YAVUZ ANACAK,Ayfer HAYDAROĞLU | 10–18 |
| Pulmonary complications of biological agents | M. Sezai TAŞBAKAN | 11–13 |
| New therapy methods in osteoarthritis | Diren ÖZER,Sibel EYİGÖR | 14–21 |
| Epidemiological and survival features of glioblastomas in Ege University Hospital | Meltem ÖZTÜRK,Serra KAMER,YEŞİM ERTAN,Erkin ÖZGİRAY,Taşkın YURTSEVEN,Ulus ŞANLI,Ayfer HAYDAROĞLU | 19–25 |
| Interventional pain treatment modalities in palliation of rheumatic pains | İdris Şevki KÖKEN,Can EYİGÖR | 22–26 |
| Epidemiological and overall survival characteristics of gynecologic cancers in Ege University Hospital database | Ayfer HAYDAROĞLU,Zeynep ÖZSARAN,Ulus Ali ŞANLI,Osman ZEKİOĞLU,NURİ YILDIRIM,Levent AKMAN,Mustafa Coşan TEREK,Ahmet Aydın ÖZSARAN | 26–32 |
| Rational use of analgesics with regard to the interactions with disease-modifying anti-rheumatic drugs | Aytül ÖNAL | 27–33 |
| Epidemiologic fetaures and survival outcomes of carcinoma of the corpus uteri | Levent AKMAN,NURİ YILDIRIM,Mustafa Coşan TEREK,Zeynep ÖZSARAN,Senem ALANYALI,Ayfer HAYDAROĞLU,Ulus ŞANLI,Erdem GÖKER,Osman ZEKİOĞLU,Necmettin ÖZDEMİR,Ahmet Aydın ÖZSARAN | 33–38 |
| Immune checkpoint inhibitors related connective tissue diseases |